Filing Flows › Indivior Pharmaceuticals (INDV) › Gross margin
Indivior Pharmaceuticals (INDV) gross margin by quarter
Indivior Pharmaceuticals' gross margin was 85.7% in Q3 2026 (third quarter 2026), -0.0 pts from Q2 2026. Over the last 7 quarters it ranged from 73.2% (Q3 2025) to 87.4% (Q1 2026).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 85.7% | -0.0 pts | +12.4 pts |
| Q2 2026 | 85.7% | -1.7 pts | +2.9 pts |
| Q1 2026 | 87.4% | +5.8 pts | +4.3 pts |
| Q4 2025 | 81.6% | +8.3 pts | — |
| Q3 2025 | 73.2% | -9.5 pts | — |
| Q2 2025 | 82.8% | -0.3 pts | — |
| Q1 2025 | 83.1% | — | — |
Q3 2026 at a glance
Indivior Pharmaceuticals, Q3 2026: revenue $356M (+13% year over year), operating margin 50.6%, net earnings $137M, operating cash flow $97.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Indivior Pharmaceuticals' gross margin?
Indivior Pharmaceuticals' gross margin was 85.7% in Q3 2026 (third quarter 2026), -0.0 pts from Q2 2026.
How has Indivior Pharmaceuticals' gross margin changed?
Over the last 7 quarters it ranged from 73.2% (Q3 2025) to 87.4% (Q1 2026).
Q3 2026 results → · How Indivior Pharmaceuticals makes money →